A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213

BACKGROUND: Rituximab-hyper-CVAD alternating with rituximab-high-dose methotrexate and cytarabine is a commonly utilized regimen in the United States for mantle cell lymphoma (MCL) based on phase II single institutional data. To confirm the clinical efficacy of this regimen and determine its feasibi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Bernstein, S. H., Epner, E., Unger, J. M., LeBlanc, M., Cebula, E., Burack, R., Rimsza, L., Miller, T. P., Fisher, R. I.
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2013
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3660082/
https://ncbi.nlm.nih.gov/pubmed/23504948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt070
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares